Alios Purchase Boosts J&J Anti-Infectives Game, Especially Hep C
This article was originally published in The Pink Sheet Daily
Executive Summary
A pair of promising preclinical nucleoside polymerase inhibitors for hepatitis C might be the driving force behind J&J’s $1.75 billion buyout of Alios, even though the privately held biotech’s most advanced candidate, ALS-8176, in Phase II for respiratory syncytial virus, also is a fit for J&J’s anti-infective strategy.